OraSure Technologies

Executive Summary

OraSure Technologies is a leading diagnostics company with over 30 years of expertise in non-invasive, rapid oral fluid testing. The company's core platforms enable accurate point-of-care and at-home screening for critical infectious diseases such as HIV, HCV, and COVID-19, as well as substance abuse detection. By leveraging its proven immunoassay and specimen stabilization technologies, OraSure has established a strong presence in public health and clinical markets. With a market capitalization of approximately $213 million, the company continues to innovate and expand its product portfolio to address unmet diagnostic needs globally. Looking ahead, OraSure is well-positioned to benefit from the growing demand for decentralized testing and self-administered diagnostics. The company is expected to drive growth through new product launches, strategic partnerships, and geographic expansion. Key near-term catalysts include potential FDA clearance of a next-generation rapid COVID-19 test, expansion of its HIV self-test into new international markets, and upcoming quarterly earnings that could provide positive guidance. While the diagnostics space remains competitive, OraSure's long-standing reputation and proprietary technology provide a solid foundation for sustained value creation.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance of Next-Generation Rapid COVID-19 Test60% success
• Q4 2026Expansion of HIV Self-Test Distribution in New Markets70% success
• Q3 2026Q3 2026 Earnings Beat and Raised Guidance50% success